Here’s what you should know.
1. Both Ferring and Rebiotix are creating human microbiome-based treatments.
2. Rebiotix’s most advanced treatment is in the midst of a phase 3 study documenting its effectiveness in preventing Clostridium difficile.
3. The FDA awarded Rebiotix’s therapy both fast track and orphan drug designation.
4. Rebiotix Founder, President and CEO Lee Jones said, “Ferring shares our passion for understanding the role the microbiome plays in human health and has global capabilities that offer huge potential for the investigational therapies that we have in development. Rebiotix was founded to revolutionize healthcare by harnessing the power of the human microbiome and this is a significant milestone in achieving that goal.”
5. Ferring said the acquisition will strengthen its development pipeline and complement its research and development capabilities.
More articles on gastroenterology:
NueHealth adds 3 senior executives
10 cars gastroenterologists are most likely to drive
Omni Eye Services purchases Pennsylvania-based eye center: 5 key points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
